WVE
Wave Life Sciences, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 9 ▼ 4 insiders sell $258.0K at $13.45
- Feb 26 ▼ 1 insider sell $499.6K at $15.05
- Mar 26 to Mar 30 ▲ 3 days of insider buys: $54.6M by 1 insider, avg $6.23
- Mar 26 ▲ Wave Life Sciences released positive Phase 1 data for WVE-007, an in…
- May 18 ▲ Wave Life Sciences reported strong updated Phase 1b/2a data for WVE-…
- Jun 24 FDA: Wave Life Sciences Announces Initiation of Phase 2a Portio…
- Aug 11 to Aug 12 ▼ 2 days of insider sells: $135.1K by 4 insiders, avg $5.63
- Sep 30 ▲ 3 funds open new positions (13F)
- Sep 30 Contract: Wave Life Sciences Announces GSK’s Selection of siRNA prog…
- Oct 16 William Blair initiates
- Oct 27 ▲ Wave Life Sciences reported Q3 2026 revenue of $13.2M (up 73% YoY fr…
- Nov 13 FDA: Wave Life Sciences Highlights WVE-007 (INHBE siRNA) Progre…
Signal stack
Where each data set points today.
- InsidersBULLISH
1 insider bought $54.6M at an average $6.23. 8 insiders sold $892.6K. Price is 54% below their cost.
- InstitutionsBEARISH
Q3 2026: 5 added (3 new), 8 trimmed or exited. Largest new: Marshall Wace $13.6M, Ubs Group Ag $10.7M.
- AnalystsBULLISH
23 of 25 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest −2.5% to 20.65M shares. 6.8 days to cover, ≈10.5% of shares.
- TrendRANGE
22% below its 50-day average. New closing low $2.87 on Nov 16.
- SocialQUIET
No Reddit mentions this week. Last mention Nov 3.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| Qube Research & Technologies Ltd | ADD | $13.6M |
| MARSHALL WACE, LLP | NEW | $13.6M |
| UBS Group AG | NEW | $10.7M |
| Aberdeen Group plc | NEW | $10.4M |
| MORGAN STANLEY | EXIT | $0.00 |
| Squarepoint Ops LLC | EXIT | $0.00 |
| VANGUARD CAPITAL MANAGEMENT LLC | EXIT | $0.00 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | EXIT | $0.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
25 analystsPrice is below the lowest target. Median implies +388%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 12, 2026 | Citigroup MAINTAIN | Buy |
| Nov 9, 2026 | B. Riley Securities REITERATE | Buy |
| Oct 29, 2026 | Canaccord Genuity MAINTAIN | Buy |
| Oct 28, 2026 | Oppenheimer MAINTAIN | Outperform |
| Oct 16, 2026 | William Blair INITIATE | Outperform |
| Oct 15, 2026 | UBS INITIATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
CORRIGAN MARK Director Oct 5, 2026 | AWARD | 10,700 sh |
CORRIGAN MARK Director Oct 5, 2026 | AWARD | 64,000 sh |
RA CAPITAL MANAGEMENT, L.P. Director Oct 5, 2026 | AWARD | 10,700 sh |
HENRY CHRISTIAN O Director Oct 5, 2026 | AWARD | 10,700 sh |
Verdine Gregory L. Director Oct 5, 2026 | AWARD | 10,700 sh |
HENRY CHRISTIAN O Director Oct 5, 2026 | AWARD | 64,000 sh |
RA CAPITAL MANAGEMENT, L.P. Director Oct 5, 2026 | AWARD | 64,000 sh |
Rawcliffe Adrian Director Oct 5, 2026 | AWARD | 10,700 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
12 filings · 4 press releases · 3 bullish · 0 bearish · 1 mixed · 8 neutral- NEUTRAL PRESS RELEASENov 13, 2026
Wave Life Sciences presented Phase 1 data for WVE-007, an siRNA targeting INHBE for obesity, at…
The Phase 1 data support continued development but are early and from a relatively low-BMI cohort. The key catalyst is the Phase 2a six-month data in 2027, which will include body composition and…
- NEUTRAL SC 13GOct 27, 2026
BlackRock filed a Schedule 13G disclosing a 6.8% passive stake in Wave Life Sciences as of…
BlackRock's re-entry at a 6.8% stake signals institutional conviction following positive regulatory news for WVE-006. Monitor for additional 13F filings from other large holders (Ra Capital…
- NEUTRAL SC 13G/AOct 27, 2026
BlackRock filed an amended Schedule 13G reporting a passive stake in Wave Life Sciences as of…
BlackRock's exit is a routine portfolio adjustment by a passive index/asset manager and does not signal a negative view on the company. The filing coincides with positive earnings news (FDA…
- BULLISH 8-KOct 27, 2026
Wave Life Sciences reported Q3 2026 revenue of $13.2M (up 73% YoY from $7.6M) and a GAAP net loss…
Watch for upcoming data from the WVE-006 600mg multidose cohort and Phase 1 600mg SAD cohort of WVE-007 in Q4 2026, and the initiation of the post-incretin maintenance trial for WVE-007. The…
All WVE filing & press-release reports (16)
- PRESS-RELEASE reportNov 13, 2026
- SC 13G reportOct 27, 2026
- SC 13G/A reportOct 27, 2026
- 8-K reportOct 27, 2026
- PRESS-RELEASE reportOct 27, 2026
- DEF 14A reportOct 14, 2026
- PRESS-RELEASE reportSep 30, 2026
- CLUSTER reportAug 13, 2026
- PRESS-RELEASE reportMay 18, 2026
- 8-K reportApr 28, 2026
- PRESS-RELEASE reportApr 28, 2026
- PRESS-RELEASE reportApr 22, 2026
- DEFA14A reportApr 15, 2026
- 8-K reportApr 15, 2026
- PRESS-RELEASE reportMar 26, 2026
- 8-K reportFeb 26, 2026